Literature DB >> 33098037

Vasculometabolic effects in patients with congenital growth hormone deficiency with and without GH replacement therapy during adulthood.

Isabela Peixoto Biscotto1, Valéria Aparecida Costa Hong2, Rafael Loch Batista3, Berenice Bilharinho Mendonca3, Ivo Jorge Prado Arnhold3, Luiz Aparecido Bortolotto2, Luciani Renata Silveira Carvalho4.   

Abstract

PURPOSE: To evaluated the metabolic profiles and vascular properties in congenital growth hormone (GH) deficiency (GHD) and its replacement in adults. PATIENTS AND METHODS: Cross-sectional study conducted in a single tertiary center for pituitary diseases. Eighty-one adult subjects were divided into three groups: (1) 29 GHD patients with daily subcutaneous GH replacement therapy (GHRT) during adulthood; (2) 20 GHD patients without GHRT during adulthood and (3) 32 controls. Only patients with adequate adherence to others pituitary hormone deficiencies were included. Anthropometric parameters, body composition by dual-energy X-ray absorptiometry, metabolic profiles and vascular properties (carotid intima media thickness, pulse wave velocity and flow-mediated dilation) were compared among the groups.
RESULTS: Waist-to-height ratio (WHR), body fat percentages and fat mass index (FMI) were lower in patients with GHRT than patients without GHRT during adulthood (0.49 ± 0.06 vs. 0.53 ± 0.06 p = 0.026, 30 ± 10 vs. 40 ± 11 p = 0.003 and 7.3 ± 4 vs. 10 ± 3.5 p = 0.041, respectively). In addition, association between longer GHRT and lower body fat percentage was observed (r =  - 0.326, p = 0.04). We found higher triglyceride (113.5 ± 62 vs. 78 ± 36, p = 0.025) and lower HDL cholesterol (51 ± 17 vs. 66 ± 23, p = 0.029) levels in patients without GHRT during adulthood in comparison to controls. No statistical differences were observed for vascular properties among the groups.
CONCLUSIONS: No differences in vascular properties were observed in congenital GHD adult patients with or without GHRT despite patients without GHRT had an unfavorable body composition. GHRT currently remains an individualized decision in adults with GHD and these findings bring new insight into the treatment and follow-up of these patients.

Entities:  

Keywords:  Cardiovascular risk; Congenital growth hormone deficiency; Growth hormone replacement therapy; Vascular system

Year:  2020        PMID: 33098037     DOI: 10.1007/s11102-020-01099-z

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  57 in total

1.  Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumor recurrence.

Authors:  B Bülow; R Attewell; L Hagmar; P Malmström; C H Nordström; E M Erfurth
Journal:  J Clin Endocrinol Metab       Date:  1998-11       Impact factor: 5.958

Review 2.  Clinical aspects of growth hormone deficiency in adults.

Authors:  H de Boer; G J Blok; E A Van der Veen
Journal:  Endocr Rev       Date:  1995-02       Impact factor: 19.871

3.  Glucocorticoid replacement and mortality in patients with nonfunctioning pituitary adenoma.

Authors:  Thomas Zueger; Paul Kirchner; Coline Herren; Stefan Fischli; Marcel Zwahlen; Emanuel Christ; Christoph Stettler
Journal:  J Clin Endocrinol Metab       Date:  2012-08-07       Impact factor: 5.958

Review 4.  Adult growth hormone deficiency: clinical advances and approaches to improve adherence.

Authors:  Kevin C J Yuen; Sofia Llahana; Bradley S Miller
Journal:  Expert Rev Endocrinol Metab       Date:  2019-11-13

5.  The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH.

Authors:  Agatha A van der Klaauw; Nienke R Biermasz; Edith J M Feskens; Marieke B Bos; Johannes W A Smit; Ferdinand Roelfsema; Eleonora P M Corssmit; Hanno Pijl; Johannes A Romijn; Alberto M Pereira
Journal:  Eur J Endocrinol       Date:  2007-04       Impact factor: 6.664

6.  Reinforcing effects of the enkephalin analogs, EK-209 and EK-399, in rats.

Authors:  N Nishida; Y Hasegawa; S Chiba; M Wakimasu; M Fujino
Journal:  Eur J Pharmacol       Date:  1989-08-03       Impact factor: 4.432

7.  Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials.

Authors:  Patrick Maison; Simon Griffin; Marc Nicoue-Beglah; Nabila Haddad; Beverley Balkau; Philippe Chanson
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

8.  The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency.

Authors:  F Salomon; R C Cuneo; R Hesp; P H Sönksen
Journal:  N Engl J Med       Date:  1989-12-28       Impact factor: 91.245

9.  Relative Risks of Contributing Factors to Morbidity and Mortality in Adults With Craniopharyngioma on Growth Hormone Replacement.

Authors:  Kevin C J Yuen; Anders F Mattsson; Pia Burman; Eva-Marie Erfurth; Cecilia Camacho-Hubner; Janet L Fox; Johan Verhelst; Mitchell E Geffner; Roger Abs
Journal:  J Clin Endocrinol Metab       Date:  2018-02-01       Impact factor: 5.958

10.  Fifteen years of GH replacement improves body composition and cardiovascular risk factors.

Authors:  Mariam Elbornsson; Galina Götherström; Ingvar Bosæus; Bengt-Åke Bengtsson; Gudmundur Johannsson; Johan Svensson
Journal:  Eur J Endocrinol       Date:  2013-04-15       Impact factor: 6.664

View more
  1 in total

1.  Quantitative measures of the vascular and neural components of the retina in adult individuals with congenital and untreated growth hormone deficiency.

Authors:  Nelmo V Menezes; Cynthia S Barros-Oliveira; Roberto Salvatori; Vinicius C Gois; Cindi G Marinho; Carla R P Oliveira; Viviane C Campos; Alécia A Oliveira-Santos; Hertz T Santos-Júnior; Elenilde G Santos; Enaldo V Melo; Augusto C N Faro; Neima V Oliveira; Hérika M Gumes-Felix; Gustavo B Melo; Manuel H Aguiar-Oliveira
Journal:  Int J Retina Vitreous       Date:  2022-10-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.